All In Biotech

Drug Trial Radar · NCT03038035

The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study

The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 2016

Primary completion

Jun 2018

Study completion Jun 2019

Sponsor

Lead sponsor
National University Hospital, SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MLC601 (Neuroaid) is a Traditional Chinese Medicine (TCM) having neuroprotective and neuroproliferative properties in cellular and animal models of brain injury. It contains 9 herbal and 5 non-herbal components. MLC901 (Neuroaid II), a simplified formula of MLC601, containing only the 9 herbal components yet showing the same efficacy has become available. This study is carried out to find out if NEUROAID II (MLC901) is safe to be taken together with other established medicines for Alzheimer's disease and whether NEUROAID II (MLC901) helps in slowing down the Alzheimer's disease progression. This study will be a 6-month randomized, double-blind, placebo-controlled trial, followed by an open extension study in which all subjects who completed the main 6 month trial (irrespective of treatment allocation) will be offered open-labelled MLC901 for another 6 months.

Conditions

  • Alzheimer Disease

Interventions

  • MLC901Drug

    24 weeks intervention with orally MLC901. 2 capsules 3 times a day

  • PlaceboDrug

    24 weeks intervention with orally placebo. 2 capsules 3 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluating the safety of MLC901 when it is given in combination with the standard treatment.The safety will be evaluated by adverse events, vital signs, ECG and laboratory tests, physical and neurological examinations at 6 months.Time frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National University Hospital

    Singapore, Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.